A clinical trial into a potential cancer vaccine is showing early ‘hopeful’ results, according to experts.
The Clatterbridge Cancer Centre in Liverpool is looking into the effectiveness of the so-called TG4050 jab in patients with head and neck cancers. All of the patients selected with the trial are administered with the vaccine following conventional treatment for their condition, Sky News has reported.
The vaccine, which is produced by French biotechnology company Transgene, is personalised from the individual patients’ own DNA, similar to the technology used in jabs made available during the Covid pandemic.
